Heather Malcolm
Directeur/Membre du Conseil chez Montana Council on Economic Education
Profil
Heather Malcolm is currently the Director at Montana Council on Economic Education.
Prior to this, she worked as the Vice President-Human Resources at Lundbeck Seattle BioPharmaceuticals, Inc. from 2008 to 2019.
Ms. Malcolm completed her undergraduate degree from St. John's College in 1994.
Postes actifs de Heather Malcolm
| Sociétés | Poste | Début |
|---|---|---|
Montana Council on Economic Education
 Montana Council on Economic Education Investment Trusts/Mutual FundsMiscellaneous Montana Council on Economic Education focuses on teacher education. The firm hosts training sessions throughout the year including workshops, conferences and seminars. Its programs include Teacher Training, High School Business Challenge, and The Stock Market Game. The company is headquartered in Bozeman, MT. | Directeur/Membre du Conseil | - |
Anciens postes connus de Heather Malcolm
| Sociétés | Poste | Fin |
|---|---|---|
| ALDER BIOPHARMACEUTICALS, INC. | Responsable des Ressources Humaines | 01/12/2019 |
Formation de Heather Malcolm
| St. John's College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Montana Council on Economic Education
Montana Council on Economic Education Investment Trusts/Mutual FundsMiscellaneous Montana Council on Economic Education focuses on teacher education. The firm hosts training sessions throughout the year including workshops, conferences and seminars. Its programs include Teacher Training, High School Business Challenge, and The Stock Market Game. The company is headquartered in Bozeman, MT. | Miscellaneous |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
